



November 10, 2017

MacroGenics Announces Poster Presentations at 32nd Annual SITC Meeting 2017

ROCKVILLE, Maryland, Nov. 10, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that five posters based on the Company's PD-1-directed franchise will be presented at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD.

Posters will be displayed in the poster hall both Friday, November 10 and Saturday, November 11. Presentation details are provided below:

MGA012 (anti-PD-1 monoclonal antibody):

P249: "A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics (PK) of MGA012 (anti-PD-1 Antibody) in Patients with Advanced Solid Tumors"

P336: "Preclinical Characterization of MGA012, a Novel Clinical-stage PD-1 Monoclonal Antibody"

MGD013 (PD-1 x LAG-3 bispecific DART® molecule):

P244: "A Phase 1, First-in-Human, Open-label, Dose Escalation Study of MGD013, a Bispecific DART Protein Binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms"

P337: "Preclinical Characterization of MGD013, a PD-1 x LAG-3 Bispecific DART Molecule"

MGD019 (PD-1 x CTLA-4 bispecific DART molecule):

P308: "A PD-1 x CTLA-4 Bispecific DART Protein with Optimal Dual Checkpoint Blockade and Favorable Tolerability in Non-human Primates"

The above posters are available for download from the Events & Presentations page on MacroGenics' website at <http://ir.macrogenics.com/events.cfm>.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, and DART are trademarks or registered trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and

similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risk factors described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

###

CONTACT:

Jim Karrels, Senior Vice President, CFO

MacroGenics, Inc.

1-301-251-5172, info@macrogenics.com

Karen Sharma

MacDougall Biomedical Communications

1-781-235-3060, ksharma@macbiocom.com